Clinical Applications of Gonadotropins in the Female: Assisted Reproduction and Beyond

Progress in Molecular Biology and Translational Science

Volumn 143, Issue , 2016, Pages 85-119

  Casarini, L ^a   Brigante, G ^a,b   Simoni, M ^a,b   Santi, D ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b AUSL Modena   (Italy)

Author keywords

ART; cancer; controlled ovarian stimulation; FSH; gonadotropin; hCG; hormone interactions; LH; OHSS

Indexed keywords

BIOSIMILAR AGENT; CHORIONIC GONADOTROPIN; FOLLITROPIN; FOLLITROPIN RECEPTOR; GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT HORMONE; SOMATOMEDIN;

ECTOPIC PREGNANCY; FEMALE; FEMALE GENITAL SYSTEM; HORMONE ACTION; HUMAN; IN VITRO STUDY; INFERTILITY THERAPY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NONHUMAN; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; POPULATION GENETICS; PREMATURE OVARIAN FAILURE; STIMULATION; THYROID GLAND; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; OVARY; OVULATION INDUCTION;

CLINICAL TRIALS AS TOPIC; FEMALE; GONADOTROPINS; HUMANS; OVARY; OVULATION INDUCTION; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 84999693706     PISSN: 18771173     EISSN: 18780814     Source Type: Book Series    
DOI: 10.1016/bs.pmbts.2016.08.002     Document Type: Chapter

References (149)

1. 1 Ezcurra, D., Humaidan, P., A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology. Reprod Biol Endocrinol, 12, 2014, 95.
2. 2 Hillier, S.G., Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol 179:1–2 (2001), 39–46.
3. 3 Usadi, R.S., Merriam, K.S., On-label and off-label drug use in the treatment of female infertility. Fertil Steril 103:3 (2015), 583–594.
4. 4 Wolfenson, C., Groisman, J., Couto, A.S., et al. Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online 10:4 (2005), 442–454.
5. 5 Casarini, L., Santi, D., Marino, M., Impact of gene polymorphisms of gonadotropins and their receptors on human reproductive success. Reproduction 150:6 (2015), R175–R184.
6. 6 Eastwick, P.W., Finkel, E.J., The evolutionary armistice: attachment bonds moderate the function of ovulatory cycle adaptations. Pers Soc Psychol Bull 38:2 (2012), 174–184.
7. 7 Vitzthum, V.J., The ecology and evolutionary endocrinology of reproduction in the human female. Am J Phys Anthropol 140:suppl 49 (2009), 95–136.
8. 8 Huhtaniemi, I., A short evolutionary history of FSH-stimulated spermatogenesis. Hormones 14:4 (2015), 468–478.
9. 9 Schlatt, S., Ehmcke, J., Regulation of spermatogenesis: an evolutionary biologist's perspective. Semin Cell Dev Biol 29 (2014), 2–16.
10. 10 Civetta, A., Adaptive evolution at immune system genes and deep pregnancy implantation in primates. Genomics 105:1 (2015), 17–22.
11. 11 Cole, L.A., hCG and hyperglycosylated hCG in the establishment and evolution of hemochorial placentation. J Reprod Immunol 82:2 (2009), 112–118.
12. 12 Smits, G., Campillo, M., Govaerts, C., et al. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J 22:11 (2003), 2692–2703.
13. 13 Ascoli, M., Fanelli, F., Segaloff, D.L., The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev 23:2 (2002), 141–174.
14. 14 Plunkett, J., Doniger, S., Orabona, G., et al. An evolutionary genomic approach to identify genes involved in human birth timing. PLoS Genet, 7(4), 2011, e1001365.
15. 15 Behre, H.M., Greb, R.R., Mempel, A., et al. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics 15:7 (2005), 451–456.
16. 16 Simoni, M., Casarini, L., Mechanisms in endocrinology: genetics of FSH action: a 2014-and-beyond view. Euro J Endocrinol 170:3 (2014), R91–R107.
17. 17 Tuttelmann, F., Laan, M., Grigorova, M., Punab, M., Sober, S., Gromoll, J., Combined effects of the variants FSHB -211G>T and FSHR 2039A>G on male reproductive parameters. J Clin Endocrinol Metab 97:10 (2012), 3639–3647.
18. 18 Hallast, P., Rull, K., Laan, M., The evolution and genomic landscape of CGB1 and CGB2 genes. Mol Cell Endocrinol 260–262 (2007), 2–11.
19. 19 Gromoll, J., Eiholzer, U., Nieschlag, E., Simoni, M., Male hypogonadism caused by homozygous deletion of exon 10 of the luteinizing hormone (LH) receptor: differential action of human chorionic gonadotropin and LH. J Clin Endocrinol Metab 85:6 (2000), 2281–2286.
20. 20 Muller, T., Simoni, M., Pekel, E., et al. Chorionic gonadotrophin beta subunit mRNA but not luteinising hormone beta subunit mRNA is expressed in the pituitary of the common marmoset (Callithrix jacchus). J Mol Endocrinol 32:1 (2004), 115–128.
21. 21 Perez Mayorga, M., Gromoll, J., Behre, H.M., Gassner, C., Nieschlag, E., Simoni, M., Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 85:9 (2000), 3365–3369.
22. 22 Simoni, M., Gromoll, J., Hoppner, W., et al. Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: identification and characterization of two discrete FSH receptor isoforms. J Clin Endocrinol Metab 84:2 (1999), 751–755.
23. 23 Sudo, S., Kudo, M., Wada, S., Sato, O., Hsueh, A.J., Fujimoto, S., Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Mol Hum Reprod 8:10 (2002), 893–899.
24. 24 Ryan, G.L., Feng, X., d'Alva, C.B., et al. Evaluating the roles of follicle-stimulating hormone receptor polymorphisms in gonadal hyperstimulation associated with severe juvenile primary hypothyroidism. J Clin Endocrinol Metab 92:6 (2007), 2312–2317.
25. 25 Nordhoff, V., Sonntag, B., von Tils, D., et al. Effects of the FSH receptor gene polymorphism p.N680S on cAMP and steroid production in cultured primary human granulosa cells. Reprod Biomed Online 23:2 (2011), 196–203.
26. 26 Rich, T.C., Xin, W., Mehats, C., et al. Cellular mechanisms underlying prostaglandin-induced transient cAMP signals near the plasma membrane of HEK-293 cells. Am J Physiol Cell Physiol 292:1 (2007), C319–C331.
27. 27 Casarini, L., Moriondo, V., Marino, M., et al. FSHR polymorphism p.N680S mediates different responses to FSH in vitro. Mol Cell Endocrinol 393:1–2 (2014), 83–91.
28. 28 Choi, J., Smitz, J., Luteinizing hormone and human chorionic gonadotropin: origins of difference. Mol Cell Endocrinol 383:1–2 (2014), 203–213.
29. 29 Muller, T., Gromoll, J., Simoni, M., Absence of exon 10 of the human luteinizing hormone (LH) receptor impairs LH, but not human chorionic gonadotropin action. J Clin Endocrinol Metab 88:5 (2003), 2242–2249.
30. 30 Grzesik, P., Kreuchwig, A., Rutz, C., et al. Differences in signal activation by LH and hCG are mediated by the LH/CG receptor's extracellular Hinge region. Front Endocrinol, 6, 2015, 140.
31. 31 Landomiel, F., Gallay, N., Jegot, G., et al. Biased signalling in follicle stimulating hormone action. Mol Cell Endocrinol 382:1 (2014), 452–459.
32. 32 Casarini, L., Lispi, M., Longobardi, S., et al. LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling. PloS One, 7(10), 2012, e46682.
33. 33 Casarini, L., Riccetti, L., De Pascali, F., et al. Follicle-stimulating hormone potentiates the steroidogenic activity of chorionic gonadotropin and the anti-apoptotic activity of luteinizing hormone in human granulosa-lutein cells in vitro. Mol Cell Endocrinol 422 (2016), 103–114.
34. 34 Menon, K.M., Menon, B., Regulation of luteinizing hormone receptor expression by an RNA binding protein: role of ERK signaling. Indian J Med Res 140:suppl (2014), S112–S119.
35. 35 Noma, N., Kawashima, I., Fan, H.Y., et al. LH-induced neuregulin 1 (NRG1) type III transcripts control granulosa cell differentiation and oocyte maturation. Mol Endocrinol 25:1 (2011), 104–116.
36. 36 Gupta, C., Chapekar, T., Chhabra, Y., Singh, P., Sinha, S., Luthra, K., Differential response to sustained stimulation by hCG & LH on goat ovarian granulosa cells. Indian J Med Res 135 (2012), 331–340.
37. 37 Amsterdam, A., Gold, R.S., Hosokawa, K., et al. Crosstalk among multiple signaling pathways controlling ovarian cell death. Trends Endocrinol Metab 10:7 (1999), 255–262.
38. 38 Lehert, P., Schertz, J.C., Ezcurra, D., Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol, 8, 2010, 112.
39. 39 Santi, D., Simoni, M., Biosimilar recombinant follicle stimulating hormones in infertility treatment. Expert Opin Biol Ther 14:10 (2014), 1399–1409.
40. 40 Bassett, R.M., Driebergen, R., Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reprod Biomed Online 10:2 (2005), 169–177.
41. 41 Keene, J.L., Matzuk, M.M., Otani, T., et al. Expression of biologically active human follitropin in Chinese hamster ovary cells. J Biol Chem 264:9 (1989), 4769–4775.
42. 42 van de Weijer, B.H., Mulders, J.W., Bos, E.S., Verhaert, P.D., van den Hooven, H.W., Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online 7:5 (2003), 547–557.
43. 43 Giudice, E., Crisci, C., Eshkol, A., Papoian, R., Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins. Hum Reprod 9:12 (1994), 2291–2299.
44. 44 Yarram, S.J., Jenkins, J., Cole, L.A., Brown, N.L., Sandy, J.R., Mansell, J.P., Epidermal growth factor contamination and concentrations of intact human chorionic gonadotropin in commercial preparations. Fertil Steril 82:1 (2004), 232–233.
45. 45 Kuwabara, Y., Mine, K., Katayama, A., Inagawa, T., Akira, S., Takeshita, T., Proteomic analyses of recombinant human follicle-stimulating hormone and urinary-derived gonadotropin preparations. J Reprod Med 54:8 (2009), 459–466.
46. 46 Van Dorsselaer, A., Carapito, C., Delalande, F., et al. Detection of prion protein in urine-derived injectable fertility products by a targeted proteomic approach. PloS One, 6(3), 2011, e17815.
47. 47 Imran, M., Mahmood, S., An overview of human prion diseases. Virol J, 8, 2011, 559.
48. 48 Ward, H.J., Balen, A., Will, R.G., Creutzfeldt–Jakob disease and urinary gonadotrophins. Hum Reprod 19:5 (2004), 1236–1237.
49. 49 Rose, M.P., Gaines Das, R.E., Balen, A.H., Definition and measurement of follicle stimulating hormone. Endocr Rev 21:1 (2000), 5–22.
50. 50 Howles, C.M., Loumaye, E., Giroud, D., Luyet, G., Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum Reprod 9:3 (1994), 424–430.
51. 51 Howles, C.M., Genetic engineering of human FSH (Gonal-F). Hum Reprod Update 2:2 (1996), 172–191.
52. 52 Bergh, C., What are the clinical benefits of recombinant gonadotrophins?. Recombinant follicle stimulating hormone. Hum Reprod 14:6 (1999), 1418–1420.
53. 53 Lunenfeld, B., Development of gonadotrophins for clinical use. Reprod Biomed Online 4:suppl 1 (2002), 11–17.
54. 54 Butnev, V.Y., Butnev, V.Y., May, J.V., et al. Production, purification, and characterization of recombinant hFSH glycoforms for functional studies. Mol Cell Endocrinol 405 (2015), 42–51.
55. 55 Jiang, C., Hou, X., Wang, C., et al. Hypoglycosylated hFSH has greater bioactivity than fully glycosylated recombinant hFSH in human granulosa cells. J Clin Endocrinol Metab 100:6 (2015), E852–E860.
56. 56 de Leeuw, R., Mulders, J., Voortman, G., Rombout, F., Damm, J., Kloosterboer, L., Structure-function relationship of recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 2:5 (1996), 361–369.
57. 57 Hard, K., Mekking, A., Damm, J.B., et al. Isolation and structure determination of the intact sialylated N-linked carbohydrate chains of recombinant human follitropin expressed in Chinese hamster ovary cells. Eur J Biochem/FEBS 193:1 (1990), 263–271.
58. 58 Lambert, A., Rodgers, M., Mitchell, R., et al. In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP. Hum Reprod 10:7 (1995), 1928–1935.
59. 59 Rose, T.H., Roshammar, D., Erichsen, L., Grundemar, L., Ottesen, J.T., Characterisation of population pharmacokinetics and endogenous follicle-stimulating hormone (FSH) levels after multiple dosing of a recombinant human FSH (FE 999049) in healthy women. Drugs R D 16:2 (2016), 165–172.
60. 60 Brinsden, P., Akagbosu, F., Gibbons, L.M., et al. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer. Fertil Steril 73:1 (2000), 114–116.
61. 61 de Lartigue, J., Corifollitropin alfa: a new option to treat female infertility. Drugs Today (Barc) 47:8 (2011), 583–590.
62. 62 Roger, S.D., Mikhail, A., Biosimilars: opportunity or cause for concern?. J Pharm Pharm Sci 10:3 (2007), 405–410.
63. 63 Baker, V.L., Brown, M.B., Luke, B., Conrad, K.P., Association of number of retrieved oocytes with live birth rate and birth weight: an analysis of 231,815 cycles of in vitro fertilization. Fertil Steril, 103(4), 2015 931–938 e932.
64. 64 Lombardi, A., Andreozzi, C., Pavone, V., Triglione, V., Angiolini, L., Caccia, P., Evaluation of the oligosaccharide composition of commercial follicle stimulating hormone preparations. Electrophoresis 34:16 (2013), 2394–2406.
65. 65 Cantineau, A.E., Cohlen, B.J., Heineman, M.J., Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility. Cochrane Database Syst Rev, 2, 2007, CD005356.
66. 66 van Wely, M., Kwan, I., Burt, A.L., et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev, 2, 2011, CD005354.
67. 67 Alviggi, C., Humaidan, P., Ezcurra, D., Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. Reprod Biol Endocrinol, 10, 2012, 9.
68. 68 La Marca, A., Ferraretti, A.P., Palermo, R., Ubaldi, F.M., The use of ovarian reserve markers in IVF clinical practice: a national consensus. Gynecol Endocrinol 32:1 (2016), 1–5.
69. 69 Siristatidis, C.S., Gibreel, A., Basios, G., Maheshwari, A., Bhattacharya, S., Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev(11), 2015, CD006919.
70. 70 Copperman, A.B., Benadiva, C., Optimal usage of the GnRH antagonists: a review of the literature. Reprod Biol Endocrinol, 11, 2013, 20.
71. 71 Custers, I.M., Steures, P., van der Steeg, J.W., et al. External validation of a prediction model for an ongoing pregnancy after intrauterine insemination. Fertil Steril 88:2 (2007), 425–431.
72. 72 Imani, B., Eijkemans, M.J., Faessen, G.H., Bouchard, P., Giudice, L.C., Fauser, B.C., Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril 77:1 (2002), 83–90.
73. 73 Steures, P., van der Steeg, J.W., Mol, B.W., et al. Prediction of an ongoing pregnancy after intrauterine insemination. Fertil Steril 82:1 (2004), 45–51.
74. 74 Daya, S., Gunby, J., WITHDRAWN: recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. Cochrane Database Syst Rev, 3, 2006, CD002810.
75. 75 Gholami, H., Vicari, E., Molis, M., La Vignera, S., Papaleo, E., Cappiello, F., Pregnancy outcome following in vitro fertilization-embryo transfer (IVF-ET) in women aged < 37, undergoing ovulation induction with human FSH compared with recombinant FSH: a randomised controlled study. Eur Rev Med Pharmacol Sci 14:2 (2010), 97–102.
76. 76 Pouwer, A.W., Farquhar, C., Kremer, J.A., Long-acting, F.S.H., versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst Rev, 7, 2015, CD009577.
77. 77 Olivennes, F., Howies, C.M., Borini, A., et al. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 22:suppl 1 (2011), S73–S82.
78. 78 Olivennes, F., Trew, G., Borini, A., et al. Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reprod Biomed Online 30:3 (2015), 248–257.
79. 79 Pouly, J.L., Olivennes, F., Massin, N., Celle, M., Caizergues, N., Contard, F., Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study. Reprod Biomed Online 31:3 (2015), 347–355.
80. 80 Simon, C., Garcia Velasco, J.J., Valbuena, D., et al. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen. Fertil Steril 70:2 (1998), 234–239.
81. 81 Tavaniotou, A., Albano, C., Smitz, J., Devroey, P., Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 55:1–2 (2002), 123–130.
82. 82 Tay, C.C., Use of gonadotrophin-releasing hormone agonists to trigger ovulation. Hum Fertil (Camb) 5:1 (2002), G35–G37 discussion G38–39, G41–38.
83. 83 Youssef, M.A., Van der Veen, F., Al-Inany, H.G., et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev, 10, 2014, CD008046.
84. 84 Baker, J.W., Morgan, R.L., Peckham, M.J., Smithers, D.W., Preservation of ovarian function in patients requiring radiotherapy for para-aortic and pelvic Hodgkin's disease. Lancet 1:7764 (1972), 1307–1308.
85. 85 Hill, M.J., Levy, G., Levens, E.D., Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature. Reprod Biomed Online 24:3 (2012), 261–271.
86. 86 Lehert, P., Kolibianakis, E.M., Venetis, C.A., et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol, 12, 2014, 17.
87. 87 Azziz, R., Introduction: determinants of polycystic ovary syndrome. Fertil Steril 106 (2016), 4–5.
88. 88 Goodman, N.F., Cobin, R.H., Futterweit, W., Glueck, J.S., Legro, R.S., Carmina, E., American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—Part 1. Endocr Pract 21:11 (2015), 1291–1300.
89. 89 Goodman, N.F., Cobin, R.H., Futterweit, W., Glueck, J.S., Legro, R.S., Carmina, E., American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—Part 2. Endocr Pract 21:12 (2015), 1415–1426.
90. 90 La Marca, A., Sunkara, S.K., Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 20:1 (2014), 124–140.
91. 91 Smith, V., Osianlis, T., Vollenhoven, B., Prevention of ovarian hyperstimulation syndrome: a review. Obstet Gynecol Int, 2015, 2015, 514159.
92. 92 Nastri, C.O., Ferriani, R.A., Rocha, I.A., Martins, W.P., Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 27:2–3 (2010), 121–128.
93. 93 Dieterich, M., Bolz, M., Reimer, T., Costagliola, S., Gerber, B., Two different entities of spontaneous ovarian hyperstimulation in a woman with FSH receptor mutation. Reprod Biomed Online 20:6 (2010), 751–758.
94. 94 Rizk, B., Symposium: update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online 19:1 (2009), 14–27.
95. 95 Wang, T.H., Horng, S.G., Chang, C.L., et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 87:7 (2002), 3300–3308.
96. 96 Kasum, M., New insights in mechanisms for development of ovarian hyperstimulation syndrome. Coll Antropol 34:3 (2010), 1139–1143.
97. 97 Goldsman, M.P., Pedram, A., Dominguez, C.E., Ciuffardi, I., Levin, E., Asch, R.H., Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 63:2 (1995), 268–272.
98. 98 Boothroyd, C., Karia, S., Andreadis, N., Rombauts, L., Johnson, N., Chapman, M., Consensus statement on prevention and detection of ovarian hyperstimulation syndrome. Aust New Zealand J Obstet Gynaecol 55:6 (2015), 523–534.
99. 99 Faddy, M.J., Gosden, R.G., Gougeon, A., Richardson, S.J., Nelson, J.F., Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 7:10 (1992), 1342–1346.
100. 100 Seifer, D.B., Scott, R.T. Jr., Bergh, P.A., et al. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertil Steril 72:1 (1999), 63–65.
101. 101 Volarcik, K., Sheean, L., Goldfarb, J., Woods, L., Abdul-Karim, F.W., Hunt, P., The meiotic competence of in-vitro matured human oocytes is influenced by donor age: evidence that folliculogenesis is compromised in the reproductively aged ovary. Hum Reprod 13:1 (1998), 154–160.
102. 102 Ferraretti, A.P., La Marca, A., Fauser, B.C., Tarlatzis, B., Nargund, G., Gianaroli, L., ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 26:7 (2011), 1616–1624.
103. 103 Farhi, J., Jacobs, H.S., Early prediction of ovarian multifollicular response during ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 67:3 (1997), 459–462.
104. 104 Nikolaou, D., Lavery, S., Turner, C., Margara, R., Trew, G., Is there a link between an extremely poor response to ovarian hyperstimulation and early ovarian failure?. Hum Reprod 17:4 (2002), 1106–1111.
105. 105 Zhao, J., Li, Y., Zhang, Q., Wang, Y., Does ovarian stimulation for IVF increase gynaecological cancer risk?. A systematic review and meta-analysis. Reprod Biomed Online 31:1 (2015), 20–29.
106. 106 Davis, P.J., Leonard, J.L., Davis, F.B., Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 29:2 (2008), 211–218.
107. 107 Flood, D.E., Fernandino, J.I., Langlois, V.S., Thyroid hormones in male reproductive development: evidence for direct crosstalk between the androgen and thyroid hormone axes. Gen Comp Endocrinol 192 (2013), 2–14.
108. 108 Kakar, S.S., Nath, S., Bunn, J., Jennes, L., The inhibition of growth and down-regulation of gonadotropin releasing hormone (GnRH) receptor in alphaT3-1 cells by GnRH agonist. Anticancer Drugs 8:4 (1997), 369–375.
109. 109 Weber, G., Vigone, M.C., Stroppa, L., Chiumello, G., Thyroid function and puberty. J Pediatr Endocrinol Metab 16:suppl 2 (2003), 253–257.
110. 110 Anasti, J.N., Flack, M.R., Froehlich, J., Nelson, L.M., Nisula, B.C., A potential novel mechanism for precocious puberty in juvenile hypothyroidism. J Clin Endocrinol Metab 80:1 (1995), 276–279.
111. 111 Negro, R., Soldin, O.P., Obregon, M.J., Stagnaro-Green, A., Hypothyroxinemia and pregnancy. Endocr Pract 17:3 (2011), 422–429.
112. 112 Poppe, K., Velkeniers, B., Female infertility and the thyroid. Best Pract Res Clin Endocrinol Metab 18:2 (2004), 153–165.
113. 113 Wakim, A.N., Polizotto, S.L., Buffo, M.J., Marrero, M.A., Burholt, D.R., Thyroid hormones in human follicular fluid and thyroid hormone receptors in human granulosa cells. Fertil Steril 59:6 (1993), 1187–1190.
114. 114 Du, D., Li, X., The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis. Int J Clin Exp Med 6:10 (2013), 880–889.
115. 115 Lindsay, A.N., Voorhess, M.L., MacGillivray, M.H., Multicystic ovaries in primary hypothyroidism. Obstet Gynecol 61:4 (1983), 433–437.
116. 116 Scoccia, B., Demir, H., Kang, Y., Fierro, M.A., Winston, N.J., In vitro fertilization pregnancy rates in levothyroxine-treated women with hypothyroidism compared to women without thyroid dysfunction disorders. Thyroid 22:6 (2012), 631–636.
117. 117 van den Boogaard, E., Vissenberg, R., Land, J.A., et al. Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review. Hum Reprod Update 17:5 (2011), 605–619.
118. 118 Busnelli, A., Somigliana, E., Ferrari, S., et al. The long-term impact of controlled ovarian hyperstimulation on thyroid function. Endocr Pract 22:4 (2016), 389–395.
119. 119 Gracia, C.R., Morse, C.B., Chan, G., et al. Thyroid function during controlled ovarian hyperstimulation as part of in vitro fertilization. Fertil Steril 97:3 (2012), 585–591.
120. 120 Chan, S.Y., Vasilopoulou, E., Kilby, M.D., The role of the placenta in thyroid hormone delivery to the fetus. Nat Clin Pract Endocrinol Metab 5:1 (2009), 45–54.
121. 121 Colicchia, M., Campagnolo, L., Baldini, E., Ulisse, S., Valensise, H., Moretti, C., Molecular basis of thyrotropin and thyroid hormone action during implantation and early development. Hum Reprod Update 20:6 (2014), 884–904.
122. 122 Kurlak, L.O., Mistry, H.D., Kaptein, E., Visser, T.J., Broughton Pipkin, F., Thyroid hormones and their placental deiodination in normal and pre-eclamptic pregnancy. Placenta 34:5 (2013), 395–400.
123. 123 Loubiere, L.S., Vasilopoulou, E., Bulmer, J.N., et al. Expression of thyroid hormone transporters in the human placenta and changes associated with intrauterine growth restriction. Placenta 31:4 (2010), 295–304.
124. 124 Daftary, S.S., Gore, A.C., IGF-1 in the brain as a regulator of reproductive neuroendocrine function. Exp Biol Med 230:5 (2005), 292–306.
125. 125 Daftary, S.S., Gore, A.C., The hypothalamic insulin-like growth factor-1 receptor and its relationship to gonadotropin-releasing hormones neurones during postnatal development. J Neuroendocrinol 16:2 (2004), 160–169.
126. 126 Chandrashekar, V., Bartke, A., The role of insulin-like growth factor-I in neuroendocrine function and the consequent effects on sexual maturation: inferences from animal models. Reprod Biol 3:1 (2003), 7–28.
127. 127 Chandrashekar, V., Zaczek, D., Bartke, A., The consequences of altered somatotropic system on reproduction. Biol Reprod 71:1 (2004), 17–27.
128. 128 Giudice, L.C., van Dessel, H.J., Cataldo, N.A., Chandrasekher, Y.A., Yap, O.W., Fauser, B.C., Circulating and ovarian IGF binding proteins: potential roles in normo-ovulatory cycles and in polycystic ovarian syndrome. Prog Growth Factor Res 6:2–4 (1995), 397–408.
129. 129 Kwintkiewicz, J., Giudice, L.C., The interplay of insulin-like growth factors, gonadotropins, and endocrine disruptors in ovarian follicular development and function. Semin Reprod Med 27:1 (2009), 43–51.
130. 130 Baumgarten, S.C., Convissar, S.M., Fierro, M.A., Winston, N.J., Scoccia, B., Stocco, C., IGF1R signaling is necessary for FSH-induced activation of AKT and differentiation of human Cumulus granulosa cells. J Clin Endocrinol Metab 99:8 (2014), 2995–3004.
131. 131 Detti, L., Uhlmann, R.A., Fletcher, N.M., Diamond, M.P., Saed, G.M., Endometrial signaling pathways during ovarian stimulation for assisted reproduction technology. Fertil Steril 100:3 (2013), 889–894.
132. 132 Pierce, J.G., Parsons, T.F., Glycoprotein hormones: structure and function. Annu Rev Biochem 50 (1981), 465–495.
133. 133 Nunez Miguel, R., Sanders, J., Chirgadze, D.Y., Blundell, T.L., Furmaniak, J., Rees Smith, B., FSH and TSH binding to their respective receptors: similarities, differences and implication for glycoprotein hormone specificity. J Mol Endocrinol 41:3 (2008), 145–164.
134. 134 Nakabayashi, K., Matsumi, H., Bhalla, A., et al. Thyrostimulin, a heterodimer of two new human glycoprotein hormone subunits, activates the thyroid-stimulating hormone receptor. J Clin Invest 109:11 (2002), 1445–1452.
135. 135 Sun, S.C., Hsu, P.J., Wu, F.J., Li, S.H., Lu, C.H., Luo, C.W., Thyrostimulin, but not thyroid-stimulating hormone (TSH), acts as a paracrine regulator to activate the TSH receptor in mammalian ovary. J Biol Chem 285:6 (2010), 3758–3765.
136. 136 Moyle, W.R., Campbell, R.K., Myers, R.V., Bernard, M.P., Han, Y., Wang, X., Co-evolution of ligand-receptor pairs. Nature 368:6468 (1994), 251–255.
137. 137 Yoshimura, M., Hershman, J.M., Thyrotropic action of human chorionic gonadotropin. Thyroid 5:5 (1995), 425–434.
138. 138 Yoshimura, M., Hershman, J.M., Pang, X.P., Berg, L., Pekary, A.E., Activation of the thyrotropin (TSH) receptor by human chorionic gonadotropin and luteinizing hormone in Chinese hamster ovary cells expressing functional human TSH receptors. J Clin Endocrinol Metab 77:4 (1993), 1009–1013.
139. 139 Carayon, P., Amr, S., Nisula, B., Lissitzky, S., Effect of carboxypeptidase digestion of the human choriogonadotropin molecule on its thyrotropic activity. Endocrinology 108:5 (1981), 1891–1898.
140. 140 Kohn, L.D., Shimura, H., Shimura, Y., et al. The thyrotropin receptor. Vitam Horm 50 (1995), 287–384.
141. 141 Krieger, C.C., Neumann, S., Place, R.F., Marcus-Samuels, B., Gershengorn, M.C., Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins. J Clin Endocrinol Metab 100:3 (2015), 1071–1077.
142. 142 Hsu, S.Y., Liang, S.G., Hsueh, A.J., Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region. Mol Endocrinol 12:12 (1998), 1830–1845.
143. 143 Govindaraj, V., Arya, S.V., Rao, A.J., Differential action of glycoprotein hormones: significance in cancer progression. Horm Cancer 5:1 (2014), 1–10.
144. 144 Mertens-Walker, I., Baxter, R.C., Marsh, D.J., Gonadotropin signalling in epithelial ovarian cancer. Cancer Lett 324:2 (2012), 152–159.
145. 145 Kolch, W., Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6:11 (2005), 827–837.
146. 146 Breckwoldt, M., Selvaraj, N., Aharoni, D., et al. Expression of Ad4-BP/cytochrome P450 side chain cleavage enzyme and induction of cell death in long-term cultures of human granulosa cells. Mol Hum Reprod 2:6 (1996), 391–400.
147. 147 Schiffer, D., Cavalla, P., Migheli, A., Giordana, M.T., Chiado-Piat, L., Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J Neurooncol 27:2 (1996), 101–109.
148. 148 Evans, J., Hyperglycosylated hCG: a unique human implantation and invasion factor. Am J Reprod Immunol 75:3 (2016), 333–340.
149. 149 Sisinni, L., Landriscina, M., The role of human chorionic gonadotropin as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol 867 (2015), 159–176.